Lead Product(s) : SPL84-23
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Biotel Limited
Deal Size : $28.5 million
Deal Type : Series B Financing
SpliSense Secures $28.5 Million in Series B Financing
Details : Proceeds will be used to advance the Company’s pipeline, including its lead Anti Sense Oligonucleotide product, SPL84-23. SPL84-23 to treat the 3849+10kb C->T CFTR mutation, that has showed ability to completely restore CFTR channel function in patient...
Product Name : SPL84-23
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
May 13, 2021
Lead Product(s) : SPL84-23
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Biotel Limited
Deal Size : $28.5 million
Deal Type : Series B Financing